Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Ramantamig (JNJ-79635322), a novel TCE trispecific mAb targeting BCMA, GPRC5D, and CD3, shows potent cytotoxicity in cancer cell lines with T-cell activation + in a murine xenograft prevention model; Phase I studies ongoing.”
Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models
Authors: Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro, Jianhong Yao, Melissa Smith, Peter Vulfson, James Testa, Jr, Randolph Ponticiello, Scott R Brodeur, Bradley Heidrich, Kathryn Packman, Sanjaya Singh, Ricardo M Attar, Yusri A Elsayed, Ulrike Philippar
You can read the Full Article in Blood.
You can find more posts featuring Robert Orlowski on OncoDaily.
